Antibodies News and Research

RSS

Hendra virus treatment to be ready in a few months

Of the dozen people who were exposed to a horse infected with the Hendra virus, 11 have been cleared of the infection by repeated tests on Queensland's Sunshine Coast. These 12 people had first come into contact with the infected horse at Tewantin in May and have since then been subjected to testing to rule out infection with the deadly virus. It is expected that the 12th person will also be cleared soon. Quarantine restrictions were also lifted last month.

14 Jul 2010

BioInvent reports net revenues of SEK 63.1M for January - June 2010 period

BioInvent reached an important milestone when the results of a phase II trial of TB-402 following orthopaedic surgery, were reported in May. The data showed that TB-402 is statistically better at preventing thrombosis than enoxaparin, the current standard treatment. Supported by these good results, BioInvent and the company's partner, ThromboGenics, will now prioritise securing a development partner for the programme to ensure that the necessary resources is in place to take the product candidate to the market.

14 Jul 2010

Scientists discover three human antibodies that neutralize HIV

Scientists have discovered three previously unknown human antibodies that neutralize HIV, two of which target a broad range of HIV strains. The findings, reported online July 8 in two Science papers, add a level of encouragement to the AIDS vaccine research field.

14 Jul 2010

New research studies presented at Alzheimer's Association International Conference

The primary therapeutic target in Alzheimer's disease has been the beta amyloid peptide, which clusters outside cells in the brain to form sticky clumps known as plaques. Recently, more attention has been given to the tau protein, which aggregates inside the brain cells of people with Alzheimer's, forming neurofibrillary tangles. Precisely how these proteins interact in causing the disease is unclear.

14 Jul 2010

LSBio announces exclusive distribution agreements with select strategic partners

LifeSpan BioSciences, Inc., a leading provider of antibodies to researchers worldwide, today announced exclusive distribution agreements with select strategic partners making the full LSBio catalog of 75,000 antibodies, including 3,600 IHC-validated, IHC-plus antibodies, available around the globe.

14 Jul 2010

Researchers investigate oral cancer, periodontal disease relationship

Today during the 88th General Session & Exhibition of the International Association for Dental Research, in Barcelona, Spain, presenting author J. Meyle, Justus Liebig University, Giessen, Germany, will present an abstract titled "P. gingivalis Infection and Immune Evasion of Oral Carcinomas."

14 Jul 2010

Administration to unveil first national HIV/AIDS strategy today

The White House will unveil the first formal national HIV/AIDS strategy on Tuesday, a plan that aims to reduce the number of new cases by 25 percent in the next five years, officials said. Noting that the number of new infections in the United States has been static -- and that the number of people living with HIV is growing -- the new policy would direct more resources toward African Americans and gay and bisexual men. Latinos and substance abusers should also be a priority, the report says.

14 Jul 2010

Stem cell transplantation from healthy donor helps cure aggressive form of CLL

The transplantation of stem cells from a healthy donor (allogeneic) offers the chance of cure for patients with an aggressive form of chronic lymphocytic leukemia (CLL), irrespective of genetic prognostic factors and the prior course of the disease. The German CLL Study Group proved this in a multicentric clinical phase II study led by Professor Dr. Peter Dreger, senior consultant and head of the division of stem cell transplantation at the Department of Internal Medicine V at Heidelberg University Hospital.

13 Jul 2010

AnaptysBio awarded DARPA contract to generate novel high affinity thermally stable antibodies

AnaptysBio, Inc., a privately-held therapeutic antibody platform and product company, today announced it has been awarded a contract by the Defense Advanced Research Projects Agency (DARPA), to use its proprietary somatic hypermutation (SHM) technology platform to generate novel high affinity thermally stable antibodies that could be used by the military in antibody-based biosensors, including those that can detect bioterrorist threats.

13 Jul 2010

Irvine Scientific opens new Industrial Cell Culture media production facility in Tokyo, Japan

Irvine Scientific, a member of JX Holdings group, announced today the opening of a new Industrial Cell Culture media production facility in Tokyo, Japan. The new facility, located in Saitama prefecture, will manufacture the Company's cell culture media for production of biopharmaceuticals, vaccines, monoclonal antibodies and other media's used in pharmaceuticals, medicines, and research. The facility is being commissioned and validated as completely animal component free manufacturing facility.

12 Jul 2010

Biogen Idec, Swedish Orphan Biovitrum announce advancement of rFVIIIFc into registrational study

Biogen Idec and Swedish Orphan Biovitrum today announced that they plan to advance the companies' long-lasting, fully-recombinant factor VIII Fc fusion protein (rFVIIIFc) into a registrational clinical trial in people with hemophilia A. The decision to advance the program is based on promising data from a Phase 1/2a open-label, cross-over, multi-center, dose-escalation study that evaluated the safety and pharmacokinetics of an intravenous injection of rFVIIIFc in 16 previously-treated patients with severe hemophilia A.

12 Jul 2010

Discovery of antibodies that kill more than 90% of HIV viruses gives new hope for vaccine

"An effective vaccine against the AIDS virus may have moved one step closer to reality, researchers said Thursday," the Los Angeles Times reports. "Federal researchers have identified a pair of naturally occurring antibodies that are able to kill more than 90% of all strains of the AIDS virus, a finding they say could lead to the development of new treatments for HIV infections and to the production of the first successful vaccine against the virus" (Maugh, 7/9).

12 Jul 2010

Adimab announces initiation of research collaboration with Novartis

Adimab, Inc., a leader in the discovery of fully human antibodies, today announced the initiation of a research collaboration with Novartis (Basel, Switzerland). This agreement represents the fifth major partnership Adimab has announced since launching its platform at BIO 2009 in Atlanta, just one year ago. In addition, Adimab today announced the receipt of a second milestone payment from its ongoing collaboration with Merck and Co.

9 Jul 2010

SurModics to present four scientific posters on drug delivery technologies at CRS Annual Meeting

SurModics, Inc., a leading provider of drug delivery and surface modification technologies to the healthcare industry, is participating at the 37th Annual Meeting and Exposition of the Controlled Release Society, July 10-14, 2010 in Portland, Oregon (booth #521).

9 Jul 2010

HHS to give states $25 million for HIV drugs; Researchers identify antibodies that may help in AIDS vaccine research

Health and Human Services Secretary Kathleen Sebelius said Thursday "that she would provide $25 million more to help states buy life-saving medications for people with H.I.V. or AIDS. Advocates for patients said the money was not nearly enough to eliminate waiting lists, which have surged to record levels as people have lost health insurance, along with their jobs, and states have cut their budgets. Ms. Sebelius said she was 'reallocating and transferring $25 million in existing resources' to provide medicines for people on waiting lists.

9 Jul 2010

Researcher uses biopharmaceutical proteases to develop novel therapy for Alzheimer's disease

A University of Oklahoma researcher is developing a novel therapy for Alzheimer's disease using "biopharmaceutical proteases" to attack the toxic plaque that builds up in the brain of an Alzheimer's patient-an approach that he predicts will be lower in cost and higher in effectiveness than current therapies.

9 Jul 2010

UKPTO grants arGEN-X patent covering SIMPLE Antibody platform

arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies using its proprietary SIMPLE Antibody(TM) platform, announces that it has been granted the first patent covering the platform. The patent GB2461546B, has been granted by the UK Patent and Trademark Office (UKPTO).

9 Jul 2010

Research findings link some autoimmune disorders with cancer

Patients with a certain type of scleroderma may get cancer and scleroderma simultaneously, Johns Hopkins researchers have found, suggesting that in some diseases, autoimmunity and cancer may be linked.

8 Jul 2010

Aethlon Medical files provisional patent on behalf of ESI for exosome detection assay

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it has filed a provisional patent on behalf of its wholly owned subsidiary Exosome Sciences, Inc. (ESI), relating to the development of an assay that will allow researchers to detect exosomes in blood and other fluids.

8 Jul 2010

Millipore launches new ProRes-S media for downstream purification of monoclonal antibodies, proteins

Millipore Corporation, a leading provider of technologies, tools and services for the global life science industry, today announced the launch of its new ProRes-S media. With the addition of ProRes-S media, Millipore's purification suite now provides a complete solution for the downstream purification of monoclonal antibodies and proteins. Developed jointly with The Dow Chemical Company, ProRes-S media offers biopharmaceutical manufacturers greater flexibility and increased throughput in a smaller manufacturing footprint.

8 Jul 2010

Antibodies News and Research

Hendra virus treatment to be ready in a few months

BioInvent reports net revenues of SEK 63.1M for January - June 2010 period

Scientists discover three human antibodies that neutralize HIV

New research studies presented at Alzheimer's Association International Conference

LSBio announces exclusive distribution agreements with select strategic partners

Researchers investigate oral cancer, periodontal disease relationship

Administration to unveil first national HIV/AIDS strategy today

Stem cell transplantation from healthy donor helps cure aggressive form of CLL

AnaptysBio awarded DARPA contract to generate novel high affinity thermally stable antibodies

Irvine Scientific opens new Industrial Cell Culture media production facility in Tokyo, Japan

Biogen Idec, Swedish Orphan Biovitrum announce advancement of rFVIIIFc into registrational study

Discovery of antibodies that kill more than 90% of HIV viruses gives new hope for vaccine

Adimab announces initiation of research collaboration with Novartis

SurModics to present four scientific posters on drug delivery technologies at CRS Annual Meeting

HHS to give states $25 million for HIV drugs; Researchers identify antibodies that may help in AIDS vaccine research

Researcher uses biopharmaceutical proteases to develop novel therapy for Alzheimer's disease

UKPTO grants arGEN-X patent covering SIMPLE Antibody platform

Research findings link some autoimmune disorders with cancer

Aethlon Medical files provisional patent on behalf of ESI for exosome detection assay

Millipore launches new ProRes-S media for downstream purification of monoclonal antibodies, proteins

How to make hybridoma-based antibody discovery more efficient eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo